- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
Discovery PK and Toxicology
Prior to joining Frontage, Nicholas has over 18 years of experience at SANOFI where he held multiple positions of increasing responsibilities. He started his career in the lab as a Bioanalytical Scientist, after he obtained his MBA, he transitioned to Outsourcing Management to support R&D Projects across North America, Europe, and Asia. This scientific and operational experience provided him with an opportunity to serve as the Chief of Staff for the Global Preclinical Dept. and the NA R&D Hub. He then transitioned to a Compliance and Business Operations role in the US before expanding to oversee a global Medical Business Operation and Compliance Organization that managed Financial Regulations in 40+ countries and Compliance Regulations in 85 countries. His most recent position was with TEMPUS LABS as the Associate Vice President of Alliance Management.
Since March 2020, the number of COVID-19 cases continued to rise in the United States, which negatively affected the Group’s business. The global pandemic has limited the full capacity of the Group’s employees performing laboratory services and lowered its delivery efficiency. The Group has employed various mitigation measures focusing on the safety and well-being of its employees, customers and partners, and the continuity of its business operations to minimize the adverse impact of the pandemic. The Group’s facilities in the United States continue to operate at a reduced utilization rate.
Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Greater China. Dr. Qi has nearly 30 years of experience in research and development leadership and overseeing operations in the regulated pharmaceutical industry. In this role, Dr. Qi will be responsible for the overall leadership and strategic growth of Frontage Greater China operations.
Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.
Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA) approved Frontage Laboratories to conduct bioanalytical services to support bioequivalence studies. ANVISA certified that Frontage Laboratories meets the agency’s stringent biopharmaceutical safety guidelines allowing the company to conduct bioanalytical work on its clients drug products. The certification will be valid until August 2022. and has been published on ANVISA website (www.anvisa.gov.br.)